Cargando…

Protecting the underscreened women in developed countries: the value of HPV test

BACKGROUND: Poor attendance to cervical cancer (CC) screening is a major risk factor for CC. Efforts to capture underscreened women are considerable and once women agree to participate, the provision of longitudinal validity of the screening test is of paramount relevance. We evaluate the addition o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibáñez, Raquel, Autonell, Josefina, Sardà, Montserrat, Crespo, Nayade, Pique, Pilar, Pascual, Amparo, Martí, Clara, Fibla, Montserrat, Gutiérrez, Cristina, Lloveras, Belén, Moreno-Crespi, Judit, Torrent, Anna, Baixeras, Núria, Alejo, María, Bosch, Francesc Xavier, de Sanjosé, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137095/
https://www.ncbi.nlm.nih.gov/pubmed/25102758
http://dx.doi.org/10.1186/1471-2407-14-574
_version_ 1782331072599556096
author Ibáñez, Raquel
Autonell, Josefina
Sardà, Montserrat
Crespo, Nayade
Pique, Pilar
Pascual, Amparo
Martí, Clara
Fibla, Montserrat
Gutiérrez, Cristina
Lloveras, Belén
Moreno-Crespi, Judit
Torrent, Anna
Baixeras, Núria
Alejo, María
Bosch, Francesc Xavier
de Sanjosé, Silvia
author_facet Ibáñez, Raquel
Autonell, Josefina
Sardà, Montserrat
Crespo, Nayade
Pique, Pilar
Pascual, Amparo
Martí, Clara
Fibla, Montserrat
Gutiérrez, Cristina
Lloveras, Belén
Moreno-Crespi, Judit
Torrent, Anna
Baixeras, Núria
Alejo, María
Bosch, Francesc Xavier
de Sanjosé, Silvia
author_sort Ibáñez, Raquel
collection PubMed
description BACKGROUND: Poor attendance to cervical cancer (CC) screening is a major risk factor for CC. Efforts to capture underscreened women are considerable and once women agree to participate, the provision of longitudinal validity of the screening test is of paramount relevance. We evaluate the addition of high risk HPV test (HPV) to cervical cytology as a primary screening test among underscreened women in the longitudinal prediction of intraepithelial lesions grade 2 or worse (CIN2+). METHODS: Women were included in the study if they were older than 39 years and with no evidence of cervical cytology in the previous five years within the Public Primary Health Care System in Catalonia (Spain). 1,832 underscreened women from eight public primary health areas were identified during 2007–2008 and followed-up for over three years to estimate longitudinal detection of CIN2+. Accuracy of each screening test and the combination of both to detect CIN2+ was estimated. The risk of developing CIN2+ lesions according to histology data by cytology and HPV test results at baseline was estimated using the Kaplan–Meier method. RESULTS: At baseline, 6.7% of participants were HPV positive, 2.2% had an abnormal cytology and 1.3% had both tests positive. At the end of follow-up, 18 out of 767 (2.3%) underscreened women had a CIN2+, two of which were invasive CC. The three-year longitudinal sensitivity and specificity estimates to detect CIN2+ were 90.5% and 93.0% for HPV test and 38.2% and 97.8% for cytology. The negative predictive value was >99.0% for each test. No additional gains in validity parameters of HPV test were observed when adding cytology as co-test. The referral to colposcopy was higher for HPV but generated 53% higher detection of CIN2+ compared to cytology. CONCLUSIONS: Underscreened women had high burden of cervical disease. Primary HPV screening followed by cytology triage could be the optimal strategy to identify CIN2+ leading to longer and safe screen intervals.
format Online
Article
Text
id pubmed-4137095
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41370952014-08-19 Protecting the underscreened women in developed countries: the value of HPV test Ibáñez, Raquel Autonell, Josefina Sardà, Montserrat Crespo, Nayade Pique, Pilar Pascual, Amparo Martí, Clara Fibla, Montserrat Gutiérrez, Cristina Lloveras, Belén Moreno-Crespi, Judit Torrent, Anna Baixeras, Núria Alejo, María Bosch, Francesc Xavier de Sanjosé, Silvia BMC Cancer Research Article BACKGROUND: Poor attendance to cervical cancer (CC) screening is a major risk factor for CC. Efforts to capture underscreened women are considerable and once women agree to participate, the provision of longitudinal validity of the screening test is of paramount relevance. We evaluate the addition of high risk HPV test (HPV) to cervical cytology as a primary screening test among underscreened women in the longitudinal prediction of intraepithelial lesions grade 2 or worse (CIN2+). METHODS: Women were included in the study if they were older than 39 years and with no evidence of cervical cytology in the previous five years within the Public Primary Health Care System in Catalonia (Spain). 1,832 underscreened women from eight public primary health areas were identified during 2007–2008 and followed-up for over three years to estimate longitudinal detection of CIN2+. Accuracy of each screening test and the combination of both to detect CIN2+ was estimated. The risk of developing CIN2+ lesions according to histology data by cytology and HPV test results at baseline was estimated using the Kaplan–Meier method. RESULTS: At baseline, 6.7% of participants were HPV positive, 2.2% had an abnormal cytology and 1.3% had both tests positive. At the end of follow-up, 18 out of 767 (2.3%) underscreened women had a CIN2+, two of which were invasive CC. The three-year longitudinal sensitivity and specificity estimates to detect CIN2+ were 90.5% and 93.0% for HPV test and 38.2% and 97.8% for cytology. The negative predictive value was >99.0% for each test. No additional gains in validity parameters of HPV test were observed when adding cytology as co-test. The referral to colposcopy was higher for HPV but generated 53% higher detection of CIN2+ compared to cytology. CONCLUSIONS: Underscreened women had high burden of cervical disease. Primary HPV screening followed by cytology triage could be the optimal strategy to identify CIN2+ leading to longer and safe screen intervals. BioMed Central 2014-08-08 /pmc/articles/PMC4137095/ /pubmed/25102758 http://dx.doi.org/10.1186/1471-2407-14-574 Text en © Ibáñez et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ibáñez, Raquel
Autonell, Josefina
Sardà, Montserrat
Crespo, Nayade
Pique, Pilar
Pascual, Amparo
Martí, Clara
Fibla, Montserrat
Gutiérrez, Cristina
Lloveras, Belén
Moreno-Crespi, Judit
Torrent, Anna
Baixeras, Núria
Alejo, María
Bosch, Francesc Xavier
de Sanjosé, Silvia
Protecting the underscreened women in developed countries: the value of HPV test
title Protecting the underscreened women in developed countries: the value of HPV test
title_full Protecting the underscreened women in developed countries: the value of HPV test
title_fullStr Protecting the underscreened women in developed countries: the value of HPV test
title_full_unstemmed Protecting the underscreened women in developed countries: the value of HPV test
title_short Protecting the underscreened women in developed countries: the value of HPV test
title_sort protecting the underscreened women in developed countries: the value of hpv test
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137095/
https://www.ncbi.nlm.nih.gov/pubmed/25102758
http://dx.doi.org/10.1186/1471-2407-14-574
work_keys_str_mv AT ibanezraquel protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT autonelljosefina protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT sardamontserrat protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT cresponayade protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT piquepilar protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT pascualamparo protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT marticlara protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT fiblamontserrat protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT gutierrezcristina protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT lloverasbelen protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT morenocrespijudit protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT torrentanna protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT baixerasnuria protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT alejomaria protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT boschfrancescxavier protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest
AT desanjosesilvia protectingtheunderscreenedwomenindevelopedcountriesthevalueofhpvtest